Ginsenosides for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Research Update
Nutrients · 03.06.2026 · 18 (11) · 1806
DOI: 10.3390/nu18111806 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 03.06.2026. Verfasst von Ke Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, National Medical Products Administration (NMPA) Key Laboratory for Safety Evaluation of Cosmetics, Guangdon…. Hauptthemen laut MEDLINE: Ginsenosides, Non-alcoholic Fatty Liver Disease, Metabolic Diseases, Fatty Liver. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Metabolic-associated fatty liver disease (MAFLD) has a high prevalence of 30–40% in China and Asia, with a complex pathogenesis and no specific therapeutic drugs. Phytochemicals have become a research hotspot for MAFLD prevention, and ginsenosides, the core active components of Panax ginseng, show great potential in anti-MAFLD research. This review aims to comprehensively clarify the key mechanisms and targets of ginsenosides in preventing and treating MAFLD, to provide a theoretical basis for their application in metabolic diseases, and to promote the development of natural phytochemical resources.
Method
The literature review method was adopted to sort out the regulatory effects and molecular targets of ginsenosides in multiple pathological processes of MAFLD from published studies.
Results
Ginsenosides regulated MAFLD through multi-pathway and multi-target effects: antioxidant regulation occurred via Nuclear factor E2-related factor 2 (Nrf2)/Silent information regulator 1/6 (SIRT1/6) pathways, and anti-inflammatory regulation was achieved by inhibiting the Nuclear factor kappa-B (NF-κB)/NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. Additionally, the measures adopted improved insulin resistance and lipid metabolism disorder, suppressed hepatocyte apoptosis/pyroptosis, repaired autophagy, alleviated hepatocyte senescence, and reshaped gut microbiota to restore gut–liver axis homeostasis.
Conclusions
Ginsenosides have good potential for MAFLD prevention and treatment, but there is a prominent lack of human clinical evidence as most existing studies are only based on in vitro cell and in vivo animal models, and the synergistic mechanisms among different ginsenoside components remain unclear. Future research needs multi-omics analysis, formulation optimization, and large-sample clinical trials, and ginsenosides have broad application prospects in MAFLD intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Food Hygiene, National Medical Products Administration (NMPA) Key Laboratory for Safety Evaluation of Cosmetics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Pu…
ORCID-Profile: Longying Zha
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, K., Qin, Z., Guo, Q., Lu, J., Luo, H., & Zha, L. (2026). Ginsenosides for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Research Update. Nutrients, 18(11), 1806. https://doi.org/10.3390/nu18111806
Vancouver
Zhang K, Qin Z, Guo Q, Lu J, Luo H, Zha L. Ginsenosides for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Research Update. Nutrients. 2026;18(11):1806. doi:10.3390/nu18111806
BibTeX
@article{Zhang2026,
author = {Zhang, Ke and Qin, Zenghui and Guo, Qingjun and Lu, Jiazhi and Luo, Huiyu and Zha, Longying},
title = {Ginsenosides for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Research Update},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {11},
pages = {1806},
doi = {10.3390/nu18111806}
}
EUVIMED